Global Next-Generation Sequencing Market

Next-Generation Sequencing Comprehensive Study by Type (Pre-Sequencing Products & Services, NGS Consumables, Platforms, & Services for Platforms, Sequencing Services, NGS Data Analysis, Storage, and Management), Application (Diagnostics, Cancer Diagnostics, Infectious Disease Diagnostics, Reproductive Health Diagnostics, Other Diagnostic Applications, Drug Discovery, Agricultural and Animal Research, Other Applications), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing, Other Sequencing Technologies), End User (Academic Institutes & Research Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Other End Users) Players and Region - Global Market Outlook to 2027

Next-Generation Sequencing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Next-generation sequencing (NGS), alternatively known as high-throughput sequencing, allows sequencing of millions of DNA molecules simultaneously. This method is useful in the field of personalized medicine, genetic diseases and clinical diagnostics as it offers high throughput option with ability to perform sequencing for multiple individual at the same time. The NGS machine or NGS sequencer is flexible enough to operate tasks such as whole –genome sequencing (WGS), targeted sequencing and transcriptome analysis. The Global Next-Generation Sequencing market is expected to grow at a CAGR of 18.64% from (2019-2024) and market size is projected to reach at USD 15.87 Billion by 2024.
This growth is primarily driven by Technical Advancement in NGS platform and Ability to Provide Cost Effective Solution.

Globally, a noticeable market trend is evident Development in Portable Sequencing Technology . The Health Care sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as 10x Genomics (United States), Agilent Technologies, Inc. (United States), Beckman Coulter (A Subsidiary of Danaher), Becton, Dickinson and Company (United States), BGI (China), Eurofins Scientific (Luxembourg), F. Hoffmann-La Roche AG (Switzerland), Genewiz (United States), Illumina, Inc. (United States), Macrogen, Inc. (South Korea) and Oxford Nanopore Technologies, Ltd. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Recently in March 2018, ARUP and metagenomics company IDbyDNA, Inc. launched Explify Respiratory which is an NGS test for respiratory infections that helps physicians while diagnosing patients with pneumonia and other respiratory diseases. Using nucleic acid the test identifies over 200 common and rare bacteria and viruses.

Regulatory Insights:
In April 2018, Food and Drug Administration (FDA) finalized a guidance document, Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases, in efforts to accelerate the establishment of a regulatory approach for next generation sequencing (NGS) testing. FDA has provided a step toward integrating NGS into clinical practice, the document has rekindled the debate about t

Market Drivers
  • Technical Advancement in NGS platform
  • Ability to Provide Cost Effective Solution

Market Trend
  • Development in Portable Sequencing Technology
  • Adoption and Integration of Advanced LIMS (Laboratory Information Management System) Real-Time Tracking Method

Restraints
  • Lack of Budget in Emerging Economies
  • Lack of Awareness About NGS Technology

Opportunities
Favorable Government Initiatives and Incorporation of Big Data
Challenges
Issue Related to Ethics and Problem Associated With Interpretation of Complex Data

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Next-Generation Sequencing Study Sheds Light on
— The Next-Generation Sequencing Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Next-Generation Sequencing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Next-Generation Sequencing industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Pre-Sequencing Products & Services
  • NGS Consumables, Platforms, & Services for Platforms
  • Sequencing Services
  • NGS Data Analysis, Storage, and Management
By Application
  • Diagnostics
  • Cancer Diagnostics
  • Infectious Disease Diagnostics
  • Reproductive Health Diagnostics
  • Other Diagnostic Applications
  • Drug Discovery
  • Agricultural and Animal Research
  • Other Applications
By Technology
  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Single-molecule Real-time Sequencing
  • Nanopore Sequencing
  • Other Sequencing Technologies

By End User
  • Academic Institutes & Research Centers
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technical Advancement in NGS platform
      • 3.2.2. Ability to Provide Cost Effective Solution
    • 3.3. Market Challenges
      • 3.3.1. Issue Related to Ethics
      • 3.3.2. Problem Associated With Interpretation of Complex Data
    • 3.4. Market Trends
      • 3.4.1. Development in Portable Sequencing Technology
      • 3.4.2. Adoption and Integration of Advanced LIMS (Laboratory Information Management System) Real-Time Tracking Method
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Next-Generation Sequencing, by Type, Application, Technology, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Next-Generation Sequencing (Value)
      • 5.2.1. Global Next-Generation Sequencing by: Type (Value)
        • 5.2.1.1. Pre-Sequencing Products & Services
        • 5.2.1.2. NGS Consumables, Platforms, & Services for Platforms
        • 5.2.1.3. Sequencing Services
        • 5.2.1.4. NGS Data Analysis, Storage, and Management
      • 5.2.2. Global Next-Generation Sequencing by: Application (Value)
        • 5.2.2.1. Diagnostics
        • 5.2.2.2. Cancer Diagnostics
        • 5.2.2.3. Infectious Disease Diagnostics
        • 5.2.2.4. Reproductive Health Diagnostics
        • 5.2.2.5. Other Diagnostic Applications
        • 5.2.2.6. Drug Discovery
        • 5.2.2.7. Agricultural and Animal Research
        • 5.2.2.8. Other Applications
      • 5.2.3. Global Next-Generation Sequencing by: Technology (Value)
        • 5.2.3.1. Sequencing by Synthesis
        • 5.2.3.2. Ion Semiconductor Sequencing
        • 5.2.3.3. Single-molecule Real-time Sequencing
        • 5.2.3.4. Nanopore Sequencing
        • 5.2.3.5. Other Sequencing Technologies
      • 5.2.4. Global Next-Generation Sequencing by: End User (Value)
        • 5.2.4.1. Academic Institutes & Research Centers
        • 5.2.4.2. Hospitals & Clinics
        • 5.2.4.3. Pharmaceutical & Biotechnology Companies
        • 5.2.4.4. Other End Users
      • 5.2.5. Global Next-Generation Sequencing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Next-Generation Sequencing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 10x Genomics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agilent Technologies, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Beckman Coulter (A Subsidiary of Danaher)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Becton, Dickinson and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BGI (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eurofins Scientific (Luxembourg)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Genewiz (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Illumina, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Macrogen, Inc. (South Korea)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Oxford Nanopore Technologies, Ltd. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Next-Generation Sequencing Sale, by Type, Application, Technology, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Next-Generation Sequencing (Value)
      • 7.2.1. Global Next-Generation Sequencing by: Type (Value)
        • 7.2.1.1. Pre-Sequencing Products & Services
        • 7.2.1.2. NGS Consumables, Platforms, & Services for Platforms
        • 7.2.1.3. Sequencing Services
        • 7.2.1.4. NGS Data Analysis, Storage, and Management
      • 7.2.2. Global Next-Generation Sequencing by: Application (Value)
        • 7.2.2.1. Diagnostics
        • 7.2.2.2. Cancer Diagnostics
        • 7.2.2.3. Infectious Disease Diagnostics
        • 7.2.2.4. Reproductive Health Diagnostics
        • 7.2.2.5. Other Diagnostic Applications
        • 7.2.2.6. Drug Discovery
        • 7.2.2.7. Agricultural and Animal Research
        • 7.2.2.8. Other Applications
      • 7.2.3. Global Next-Generation Sequencing by: Technology (Value)
        • 7.2.3.1. Sequencing by Synthesis
        • 7.2.3.2. Ion Semiconductor Sequencing
        • 7.2.3.3. Single-molecule Real-time Sequencing
        • 7.2.3.4. Nanopore Sequencing
        • 7.2.3.5. Other Sequencing Technologies
      • 7.2.4. Global Next-Generation Sequencing by: End User (Value)
        • 7.2.4.1. Academic Institutes & Research Centers
        • 7.2.4.2. Hospitals & Clinics
        • 7.2.4.3. Pharmaceutical & Biotechnology Companies
        • 7.2.4.4. Other End Users
      • 7.2.5. Global Next-Generation Sequencing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Next-Generation Sequencing: by Type(USD Billion)
  • Table 2. Next-Generation Sequencing Pre-Sequencing Products & Services , by Region USD Billion (2016-2021)
  • Table 3. Next-Generation Sequencing NGS Consumables, Platforms, & Services for Platforms , by Region USD Billion (2016-2021)
  • Table 4. Next-Generation Sequencing Sequencing Services , by Region USD Billion (2016-2021)
  • Table 5. Next-Generation Sequencing NGS Data Analysis, Storage, and Management , by Region USD Billion (2016-2021)
  • Table 6. Next-Generation Sequencing: by Application(USD Billion)
  • Table 7. Next-Generation Sequencing Diagnostics , by Region USD Billion (2016-2021)
  • Table 8. Next-Generation Sequencing Cancer Diagnostics , by Region USD Billion (2016-2021)
  • Table 9. Next-Generation Sequencing Infectious Disease Diagnostics , by Region USD Billion (2016-2021)
  • Table 10. Next-Generation Sequencing Reproductive Health Diagnostics , by Region USD Billion (2016-2021)
  • Table 11. Next-Generation Sequencing Other Diagnostic Applications , by Region USD Billion (2016-2021)
  • Table 12. Next-Generation Sequencing Drug Discovery , by Region USD Billion (2016-2021)
  • Table 13. Next-Generation Sequencing Agricultural and Animal Research , by Region USD Billion (2016-2021)
  • Table 14. Next-Generation Sequencing Other Applications , by Region USD Billion (2016-2021)
  • Table 15. Next-Generation Sequencing: by Technology(USD Billion)
  • Table 16. Next-Generation Sequencing Sequencing by Synthesis , by Region USD Billion (2016-2021)
  • Table 17. Next-Generation Sequencing Ion Semiconductor Sequencing , by Region USD Billion (2016-2021)
  • Table 18. Next-Generation Sequencing Single-molecule Real-time Sequencing , by Region USD Billion (2016-2021)
  • Table 19. Next-Generation Sequencing Nanopore Sequencing , by Region USD Billion (2016-2021)
  • Table 20. Next-Generation Sequencing Other Sequencing Technologies , by Region USD Billion (2016-2021)
  • Table 21. Next-Generation Sequencing: by End User(USD Billion)
  • Table 22. Next-Generation Sequencing Academic Institutes & Research Centers , by Region USD Billion (2016-2021)
  • Table 23. Next-Generation Sequencing Hospitals & Clinics , by Region USD Billion (2016-2021)
  • Table 24. Next-Generation Sequencing Pharmaceutical & Biotechnology Companies , by Region USD Billion (2016-2021)
  • Table 25. Next-Generation Sequencing Other End Users , by Region USD Billion (2016-2021)
  • Table 26. South America Next-Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 27. South America Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 28. South America Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 29. South America Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 30. South America Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 31. Brazil Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 32. Brazil Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 33. Brazil Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 34. Brazil Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 35. Argentina Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 36. Argentina Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 37. Argentina Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 38. Argentina Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 39. Rest of South America Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 40. Rest of South America Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 41. Rest of South America Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 42. Rest of South America Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 43. Asia Pacific Next-Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 44. Asia Pacific Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 45. Asia Pacific Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 46. Asia Pacific Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 47. Asia Pacific Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 48. China Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 49. China Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 50. China Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 51. China Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 52. Japan Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 53. Japan Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 54. Japan Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 55. Japan Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 56. India Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 57. India Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 58. India Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 59. India Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 60. South Korea Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 61. South Korea Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 62. South Korea Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 63. South Korea Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 64. Taiwan Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 65. Taiwan Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 66. Taiwan Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 67. Taiwan Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 68. Australia Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 69. Australia Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 70. Australia Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 71. Australia Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 72. Rest of Asia-Pacific Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 73. Rest of Asia-Pacific Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 74. Rest of Asia-Pacific Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 75. Rest of Asia-Pacific Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 76. Europe Next-Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 77. Europe Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 78. Europe Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 79. Europe Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 80. Europe Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 81. Germany Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 82. Germany Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 83. Germany Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 84. Germany Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 85. France Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 86. France Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 87. France Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 88. France Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 89. Italy Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 90. Italy Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 91. Italy Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 92. Italy Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 93. United Kingdom Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 94. United Kingdom Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 95. United Kingdom Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 96. United Kingdom Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 97. Netherlands Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 98. Netherlands Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 99. Netherlands Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 100. Netherlands Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 101. Rest of Europe Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 102. Rest of Europe Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 103. Rest of Europe Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 104. Rest of Europe Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 105. MEA Next-Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 106. MEA Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 107. MEA Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 108. MEA Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 109. MEA Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 110. Middle East Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 111. Middle East Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 112. Middle East Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 113. Middle East Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 114. Africa Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 115. Africa Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 116. Africa Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 117. Africa Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 118. North America Next-Generation Sequencing, by Country USD Billion (2016-2021)
  • Table 119. North America Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 120. North America Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 121. North America Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 122. North America Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 123. United States Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 124. United States Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 125. United States Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 126. United States Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 127. Canada Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 128. Canada Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 129. Canada Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 130. Canada Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 131. Mexico Next-Generation Sequencing, by Type USD Billion (2016-2021)
  • Table 132. Mexico Next-Generation Sequencing, by Application USD Billion (2016-2021)
  • Table 133. Mexico Next-Generation Sequencing, by Technology USD Billion (2016-2021)
  • Table 134. Mexico Next-Generation Sequencing, by End User USD Billion (2016-2021)
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Next-Generation Sequencing: by Type(USD Billion)
  • Table 147. Next-Generation Sequencing Pre-Sequencing Products & Services , by Region USD Billion (2022-2027)
  • Table 148. Next-Generation Sequencing NGS Consumables, Platforms, & Services for Platforms , by Region USD Billion (2022-2027)
  • Table 149. Next-Generation Sequencing Sequencing Services , by Region USD Billion (2022-2027)
  • Table 150. Next-Generation Sequencing NGS Data Analysis, Storage, and Management , by Region USD Billion (2022-2027)
  • Table 151. Next-Generation Sequencing: by Application(USD Billion)
  • Table 152. Next-Generation Sequencing Diagnostics , by Region USD Billion (2022-2027)
  • Table 153. Next-Generation Sequencing Cancer Diagnostics , by Region USD Billion (2022-2027)
  • Table 154. Next-Generation Sequencing Infectious Disease Diagnostics , by Region USD Billion (2022-2027)
  • Table 155. Next-Generation Sequencing Reproductive Health Diagnostics , by Region USD Billion (2022-2027)
  • Table 156. Next-Generation Sequencing Other Diagnostic Applications , by Region USD Billion (2022-2027)
  • Table 157. Next-Generation Sequencing Drug Discovery , by Region USD Billion (2022-2027)
  • Table 158. Next-Generation Sequencing Agricultural and Animal Research , by Region USD Billion (2022-2027)
  • Table 159. Next-Generation Sequencing Other Applications , by Region USD Billion (2022-2027)
  • Table 160. Next-Generation Sequencing: by Technology(USD Billion)
  • Table 161. Next-Generation Sequencing Sequencing by Synthesis , by Region USD Billion (2022-2027)
  • Table 162. Next-Generation Sequencing Ion Semiconductor Sequencing , by Region USD Billion (2022-2027)
  • Table 163. Next-Generation Sequencing Single-molecule Real-time Sequencing , by Region USD Billion (2022-2027)
  • Table 164. Next-Generation Sequencing Nanopore Sequencing , by Region USD Billion (2022-2027)
  • Table 165. Next-Generation Sequencing Other Sequencing Technologies , by Region USD Billion (2022-2027)
  • Table 166. Next-Generation Sequencing: by End User(USD Billion)
  • Table 167. Next-Generation Sequencing Academic Institutes & Research Centers , by Region USD Billion (2022-2027)
  • Table 168. Next-Generation Sequencing Hospitals & Clinics , by Region USD Billion (2022-2027)
  • Table 169. Next-Generation Sequencing Pharmaceutical & Biotechnology Companies , by Region USD Billion (2022-2027)
  • Table 170. Next-Generation Sequencing Other End Users , by Region USD Billion (2022-2027)
  • Table 171. South America Next-Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 172. South America Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 173. South America Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 174. South America Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 175. South America Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 176. Brazil Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 177. Brazil Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 178. Brazil Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 179. Brazil Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 180. Argentina Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 181. Argentina Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 182. Argentina Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 183. Argentina Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 184. Rest of South America Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 185. Rest of South America Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 186. Rest of South America Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 187. Rest of South America Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 188. Asia Pacific Next-Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 189. Asia Pacific Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 190. Asia Pacific Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 191. Asia Pacific Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 192. Asia Pacific Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 193. China Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 194. China Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 195. China Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 196. China Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 197. Japan Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 198. Japan Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 199. Japan Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 200. Japan Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 201. India Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 202. India Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 203. India Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 204. India Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 205. South Korea Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 206. South Korea Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 207. South Korea Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 208. South Korea Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 209. Taiwan Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 210. Taiwan Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 211. Taiwan Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 212. Taiwan Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 213. Australia Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 214. Australia Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 215. Australia Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 216. Australia Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 217. Rest of Asia-Pacific Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 218. Rest of Asia-Pacific Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 219. Rest of Asia-Pacific Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 220. Rest of Asia-Pacific Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 221. Europe Next-Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 222. Europe Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 223. Europe Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 224. Europe Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 225. Europe Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 226. Germany Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 227. Germany Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 228. Germany Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 229. Germany Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 230. France Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 231. France Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 232. France Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 233. France Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 234. Italy Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 235. Italy Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 236. Italy Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 237. Italy Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 238. United Kingdom Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 239. United Kingdom Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 240. United Kingdom Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 241. United Kingdom Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 242. Netherlands Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 243. Netherlands Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 244. Netherlands Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 245. Netherlands Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 246. Rest of Europe Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 247. Rest of Europe Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 248. Rest of Europe Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 249. Rest of Europe Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 250. MEA Next-Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 251. MEA Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 252. MEA Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 253. MEA Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 254. MEA Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 255. Middle East Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 256. Middle East Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 257. Middle East Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 258. Middle East Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 259. Africa Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 260. Africa Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 261. Africa Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 262. Africa Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 263. North America Next-Generation Sequencing, by Country USD Billion (2022-2027)
  • Table 264. North America Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 265. North America Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 266. North America Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 267. North America Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 268. United States Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 269. United States Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 270. United States Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 271. United States Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 272. Canada Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 273. Canada Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 274. Canada Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 275. Canada Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 276. Mexico Next-Generation Sequencing, by Type USD Billion (2022-2027)
  • Table 277. Mexico Next-Generation Sequencing, by Application USD Billion (2022-2027)
  • Table 278. Mexico Next-Generation Sequencing, by Technology USD Billion (2022-2027)
  • Table 279. Mexico Next-Generation Sequencing, by End User USD Billion (2022-2027)
  • Table 280. Research Programs/Design for This Report
  • Table 281. Key Data Information from Secondary Sources
  • Table 282. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Next-Generation Sequencing: by Type USD Billion (2016-2021)
  • Figure 5. Global Next-Generation Sequencing: by Application USD Billion (2016-2021)
  • Figure 6. Global Next-Generation Sequencing: by Technology USD Billion (2016-2021)
  • Figure 7. Global Next-Generation Sequencing: by End User USD Billion (2016-2021)
  • Figure 8. South America Next-Generation Sequencing Share (%), by Country
  • Figure 9. Asia Pacific Next-Generation Sequencing Share (%), by Country
  • Figure 10. Europe Next-Generation Sequencing Share (%), by Country
  • Figure 11. MEA Next-Generation Sequencing Share (%), by Country
  • Figure 12. North America Next-Generation Sequencing Share (%), by Country
  • Figure 13. Global Next-Generation Sequencing share by Players 2021 (%)
  • Figure 14. Global Next-Generation Sequencing share by Players (Top 3) 2021(%)
  • Figure 15. Global Next-Generation Sequencing share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. 10x Genomics (United States) Revenue, Net Income and Gross profit
  • Figure 18. 10x Genomics (United States) Revenue: by Geography 2021
  • Figure 19. Agilent Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Agilent Technologies, Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Beckman Coulter (A Subsidiary of Danaher) Revenue, Net Income and Gross profit
  • Figure 22. Beckman Coulter (A Subsidiary of Danaher) Revenue: by Geography 2021
  • Figure 23. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. Becton, Dickinson and Company (United States) Revenue: by Geography 2021
  • Figure 25. BGI (China) Revenue, Net Income and Gross profit
  • Figure 26. BGI (China) Revenue: by Geography 2021
  • Figure 27. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 28. Eurofins Scientific (Luxembourg) Revenue: by Geography 2021
  • Figure 29. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 31. Genewiz (United States) Revenue, Net Income and Gross profit
  • Figure 32. Genewiz (United States) Revenue: by Geography 2021
  • Figure 33. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Illumina, Inc. (United States) Revenue: by Geography 2021
  • Figure 35. Macrogen, Inc. (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. Macrogen, Inc. (South Korea) Revenue: by Geography 2021
  • Figure 37. Oxford Nanopore Technologies, Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Oxford Nanopore Technologies, Ltd. (United States) Revenue: by Geography 2021
  • Figure 39. Global Next-Generation Sequencing: by Type USD Billion (2022-2027)
  • Figure 40. Global Next-Generation Sequencing: by Application USD Billion (2022-2027)
  • Figure 41. Global Next-Generation Sequencing: by Technology USD Billion (2022-2027)
  • Figure 42. Global Next-Generation Sequencing: by End User USD Billion (2022-2027)
  • Figure 43. South America Next-Generation Sequencing Share (%), by Country
  • Figure 44. Asia Pacific Next-Generation Sequencing Share (%), by Country
  • Figure 45. Europe Next-Generation Sequencing Share (%), by Country
  • Figure 46. MEA Next-Generation Sequencing Share (%), by Country
  • Figure 47. North America Next-Generation Sequencing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • 10x Genomics (United States)
  • Agilent Technologies, Inc. (United States)
  • Beckman Coulter (A Subsidiary of Danaher)
  • Becton, Dickinson and Company (United States)
  • BGI (China)
  • Eurofins Scientific (Luxembourg)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Genewiz (United States)
  • Illumina, Inc. (United States)
  • Macrogen, Inc. (South Korea)
  • Oxford Nanopore Technologies, Ltd. (United States)
Additional players considered in the study are as follows:
Pacific Biosciences of California, Inc. , Perkinelmer, Inc. , Thermo Fisher Scientific Inc. , Qiagen N.V.
Select User Access Type

Key Highlights of Report


Feb 2022 207 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Next-Generation Sequencing Market Quantitative research analysis
Global Next-Generation Sequencing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Next-Generation Sequencing market is expected to see a CAGR of % during projected year 2021 to 2027.
Top performing companies in the Global Next-Generation Sequencing market are 10x Genomics (United States), Agilent Technologies, Inc. (United States), Beckman Coulter (A Subsidiary of Danaher), Becton, Dickinson and Company (United States), BGI (China), Eurofins Scientific (Luxembourg), F. Hoffmann-La Roche AG (Switzerland), Genewiz (United States), Illumina, Inc. (United States), Macrogen, Inc. (South Korea) and Oxford Nanopore Technologies, Ltd. (United States), to name a few.
North America is dominating the Next-Generation Sequencing Market.

Know More About Global Next-Generation Sequencing Market Report?

Have a Query? Click Here

Other Related Reports

Low-temperature Freezers Comprehensive Study by Type (Chest, Upright, Undercounter), Application (Laboratory, Pharmaceuticals, Biobanks, Others), Body Material (Stainless Steel, Aluminum), Size (Smal...
$ 3800
Inactivated Vaccine Comprehensive Study by Type (By End User, Pediatrics, Adults, By Disease Indication, Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), Application (Hospital, M...
$ 3500
Pain Management Therapeutics Comprehensive Study by Type (Antidepressants, Anesthetics, NSAIDs, Opioids, Anti-Migraine Agents, Other), Application (Burn Pain, Cancer Pain, Dental/Facial Pain, Migrain...
$ 3750
Mobile Clinics Comprehensive Study by Type (Eye-wear, Mobile health, Connected medical devices, Mhealth apps), Application (Diabetes, Cardiovascular Disease, Respiratory Diseases, Neurological Diseas...
$ 3500
Dental Wax Comprehensive Study by Type (Mineral Wax, Animal Wax, Plant Wax, Synthetic Wax), Application (Hospitals, Dentist Clinics, Academic and Research Centers, Others) Players and Region - Global...
$ 3500
Marijuana Oil Comprehensive Study by Type (Organic, Inorganic), Application (Vape Cartirdges, Subligual Drops& Sprays, Topical Creams & Salves, Gummies & Edibles, Softgel Capsules, Others), End Use (...
$ 3450